Karyopharm Therapeutics: cross-border access for the specialty portfolio
Quick orientation
Karyopharm Therapeutics Inc. is a US oncology biotechnology company headquartered in Newton, Massachusetts. The company developed the first-in-class selective inhibitor of nuclear export (SINE) compound Xpovio (selinexor), which targets exportin 1 (XPO1) and is approved for relapsed or refractory multiple myeloma and relapsed or refractory diffuse large B-cell lymphoma. Karyopharm trades on NASDAQ as KPTI. FDA approval scale is one marketed product across multiple hematological oncology indications. The pipeline extends the SINE platform into endometrial cancer and myelofibrosis with additional candidates in earlier-stage development.
Karyopharm portfolio in cross-border NPP scope
Xpovio (selinexor) is an FDA-approved oral selective inhibitor of nuclear export indicated for: adult patients with relapsed or refractory multiple myeloma in combination with dexamethasone after at least four prior therapies (FDA approval July 2019 under accelerated approval); adult patients with multiple myeloma in combination with bortezomib and dexamethasone after at least one prior therapy (FDA approval December 2020); and adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after at least two lines of therapy (FDA approval June 2020 under accelerated approval). Oral dosing, once weekly. US list pricing varies by regimen and dose but is in the range of US$22,000 per month for the multiple myeloma combination regimens. The product is supplied as tablets and is shipped at ambient temperature.
Karyopharm's pipeline includes selinexor in development for endometrial cancer (the SIENDO Phase 3 program) and myelofibrosis (Phase 3 SENTRY program with ruxolitinib), as well as eltanexor (KPT-8602) in earlier-stage development. These are investigational and not in NPP scope.
Why patients route through cross-border NPP
Relapsed or refractory multiple myeloma is a setting where patients have typically exhausted multiple lines of therapy and need additional mechanistic options. Selinexor's novel mechanism - inhibition of nuclear export of tumor suppressor proteins - is distinct from the mechanisms of proteasome inhibitors, immunomodulatory drugs, anti-CD38 antibodies, and BCMA-directed therapies. For patients who have progressed on or are not candidates for those classes, Xpovio is one of few additional options with FDA-labeled use.
Xpovio commercial availability outside the United States is uneven. The European Commission approved selinexor (trade name Nexpovio in EU) for multiple myeloma, but country-by-country reimbursement and stocking remain inconsistent. In India, the GCC, Turkey, and most of MENA and Southeast Asia, patients with confirmed indication and treating hematologist prescription frequently route through cross-border NPP. Patient profile typically requires: confirmed multiple myeloma diagnosis with documentation of prior therapies and progression; or confirmed DLBCL diagnosis with documentation of prior lines of therapy; performance status preserved; and the ability to manage on-label adverse events including thrombocytopenia, nausea, and fatigue.
Common cross-border destinations
The highest-frequency NPP destinations for Xpovio from US-approved inventory are India, the United Arab Emirates, Saudi Arabia, Turkey, and Egypt. Major hematology-oncology centers in Mumbai, Bangalore, Hyderabad, Dubai, Riyadh, and Istanbul drive most inbound referrals.
Manufacturer engagement posture
Reserve Meds coordinates Karyopharm-sourced US commercial product through DSCSA-compliant US specialty distributors. We are not affiliated with Karyopharm Therapeutics. Our role is patient-facing coordination on behalf of named individual patients with a verified hematology-oncology prescription. For Karyopharm medical affairs or commercial teams interested in cross-border NPP pathways, our BD contact is [email protected].
What Reserve Meds provides
For each Xpovio request, Reserve Meds coordinates: prescription verification with the treating hematologist-oncologist; documentation review of prior lines of therapy where required for the indication; DSCSA serialized chain-of-custody from Karyopharm through licensed US wholesalers to the named patient; ambient shipping with appropriate packaging; destination-country regulatory documentation for Ministry of Health named-patient approvals and customs clearance; and a dedicated coordinator from prescription to delivery.
Clinical governance and prescription review
Every prescription for a product on this page is reviewed by a US-licensed pharmacist before dispensing. Reserve Meds does not substitute generic equivalents for branded specialty products without an explicit prescriber instruction, and we do not dispense any product whose chain-of-custody we cannot serialize back to the FDA-authorised manufacturer or its licensed wholesale partner. Our clinical review confirms indication-on-label appropriateness based on the documentation submitted by the treating physician, identifies any standard drug-drug interaction or contraindication concerns, and confirms that the requested dose, dosing schedule, and dosage form match the prescription. Where the prescription is unclear or where the indication on the prescription is off-label, our pharmacist contacts the prescriber directly. We do not provide medical advice to patients beyond drug-information counseling at dispensing.
Supply chain integrity
Supply integrity is the foundation of Reserve Meds operations. Every shipment carries a serialized DSCSA pedigree document confirming the chain of ownership from the FDA-registered manufacturer or its authorised distributor through a licensed US wholesale distributor to Reserve Meds and onward to the named patient. We do not source through parallel-import channels, third-country re-import, or unverified online wholesale markets. Cold-chain shipments are packed in qualified shippers with temperature data-loggers reading and logging temperature throughout the journey; data-logger reads are reviewed on arrival, and any out-of-specification excursion triggers our quality-hold protocol. For frozen products such as gene therapies and certain antibody-drug conjugates, we use validated frozen-shipper systems with dry-ice replenishment as required.
Destination-country regulatory pathways
Cross-border named patient access operates under jurisdiction-specific regulatory frameworks. In the United Arab Emirates, the Ministry of Health and Prevention (MOHAP) and Dubai Health Authority operate import-permit pathways for unregistered or restricted medicines on a named-patient basis. Saudi Arabia, Qatar, Kuwait, Bahrain, and Oman each operate analogous Ministry of Health named-patient frameworks with country-specific documentation requirements. India operates a personal-import pathway under the Drugs and Cosmetics Rules for quantities consistent with personal therapeutic use, typically up to three months supply per shipment. Turkey, Egypt, Jordan, Lebanon, and Morocco each operate distinct named-patient or import-permit pathways. Reserve Meds maintains current regulatory intelligence for each of these jurisdictions and prepares the documentation package required for each shipment.
What to expect through the coordination process
Patients beginning a request receive an initial coordinator contact within one business day of submission. The coordinator reviews the prescription, identifies the documentation required for the destination country, and provides an indicative cost range. Once required documents are uploaded - prescription, prescriber license verification, patient identification, and any indication-specific documentation such as genetic test results or biomarker reports - we issue a firm quote inclusive of product cost, packaging, shipping, regulatory documentation, and our coordination fee. Patients confirm acceptance of the firm quote before any sourcing or shipping is initiated, and Reserve Meds does not collect any deposit at intake. Once the firm quote is accepted and payment is received, the coordinator initiates sourcing through our licensed wholesale partners and prepares the destination-country regulatory package. Typical end-to-end timing from accepted quote to delivery is two to four weeks for ambient-shipped products and three to five weeks for cold-chain shipments, with variability driven by destination-country customs and regulatory turnaround times.
Not affiliated with the manufacturer
Reserve Meds is an independent operator of named patient program coordination. We are not a subsidiary, affiliate, authorised distributor, or licensed representative of any pharmaceutical manufacturer, and no statement on this page should be read as a partnership, endorsement, or representation by the named manufacturer. Trade names and product references on this page are used for informational purposes to identify the FDA-approved products that Reserve Meds coordinates through US specialty wholesale channels on behalf of named individual patients.
Privacy and data handling
Patient data submitted to Reserve Meds is handled under our HIPAA-aligned privacy policy and our destination-country data protection commitments. We minimise data collection to what is necessary for prescription verification, regulatory documentation, and shipping logistics. Patient identifiable information is shared with US wholesalers, destination-country regulatory authorities, and shipping carriers only as required to complete the coordination, and is not used for any marketing purpose.
Next step for patients
Patients with relapsed or refractory multiple myeloma or DLBCL and a treating-physician prescription for Xpovio can begin a request now. Start a request ›
Next step for Karyopharm teams
Karyopharm Therapeutics medical affairs or commercial teams interested in cross-border NPP coordination for non-US territories can reach our BD team at [email protected].
Reserved for you.